The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-04

Study Completion Date

2021-04-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will examine the impact on cognitive reserve of a pharmacist-physician patient-centered medication therapy management intervention to address inappropriate medication use as identified by the Beers 2015 list. By bolstering cognitive reserve, this project will directly address the National Alzheimer's Project Act 2015 priorities serving to delay onset of symptoms in preclinical dementia. The results of this study will provide valuable insights on how to expand this intervention to reduce the prevalence and associated healthcare costs of symptomatic Alzheimer's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease

NCT01841905

Alzheimer's Disease

UNKNOWN

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005

Alzheimers Disease Dementia Alzheimers Disease, Familial

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

NCT00105547

Alzheimer Disease Dementia

COMPLETED PHASE3

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

NCT03486938

Mild Cognitive Impairment Prodromal Alzheimer's Disease

COMPLETED PHASE2/PHASE3

Brain Imaging and Mental Disorders of Aging Intervention

NCT00267163

Cognition Disorders

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 12-month, parallel arm, study to be conducted at the University of Kentucky. The study will involve assessing medication use and identifying any medicines that may be inappropriate for elderly adults.

At the beginning of the study, participants will be asked to undergo one amyloid-PET scan to detect early amyloid plaques in their brain which could increase the risk of Alzheimer's disease in the near future. In addition, at the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities.

Part of the study includes collecting information regarding participants memory and thinking abilities. Participants will be asked to complete questionnaires as well as memory and thinking tests.

A study doctor will review participants medical history and then perform routine medical (physical and neurological) examinations.

Two of the study visits will be conducted by phone to check up on the participants.

At the beginning, middle, and end of the study, participants will meet with a doctor and pharmacist to review and make any changes deemed appropriate to their current medicines. This will be done in order to try and eliminate medicines that are not recommended for the elderly. These visits are referred to as the Medication Therapy Management (MTM).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Participants enrolled into this arm will only receive educational materials, but will not receive specific recommendations to make changes to the medications they are taking.

Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Participants will receive educational materials, but will not receive MTM.

Scopolamine patch

Intervention Type DRUG

At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.

Medication Therapy Management (MTM)

Participants enrolled into this arm will receive educational materials and will have their medications assessed; recommendations for changes in the medications taken will be made when appropriate.

Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve.

Group Type ACTIVE_COMPARATOR

Medication Therapy Management (MTM)

Intervention Type OTHER

Participants will receive MTM in addition to the educational materials.

Scopolamine patch

Intervention Type DRUG

At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Participants will receive educational materials, but will not receive MTM.

Intervention Type OTHER

Medication Therapy Management (MTM)

Participants will receive MTM in addition to the educational materials.

Intervention Type OTHER

Scopolamine patch

At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Control Intervention Scopolamine Challenge

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-demented
* No previous reaction or contraindication to scopolamine patch, or medical condition warranting dose adjustment in scopolamine including but not limited to: open angle glaucoma, gastrointestinal or urinary outlet obstructions, seizures, or psychosis.
* No contraindications to Aβ-PET scan including hypersensitivity to PET ligand or radiation exposures in the past year that would exceed the acceptable safe annual exposure in combination with the Aβ PET
* Medically stable and able to complete all study activities, as determined by the investigator
* Reporting at least one potentially inappropriate medication as listed in the Beers 2015 criteria
* Living in the community
* Willing to participate in this intervention study

Exclusion Criteria

* Allergy or other know intolerance to scopolamine patches
* Narrow-angle glaucoma
* Difficulty swallowing
* Stomach or bowel problems (e.g., blockage, muscle weakness, ulcerative colitis)
* Bleeding
* Acid reflux disease
* Myasthenia gravis
* Blockage of the urinary tract.
* Seizures
* Psychosis

Minimum Eligible Age

65 Years

Maximum Eligible Age

101 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No